UK markets close in 44 minutes
  • FTSE 100

    7,496.14
    -4.75 (-0.06%)
     
  • FTSE 250

    20,366.50
    +27.54 (+0.14%)
     
  • AIM

    932.44
    -0.76 (-0.08%)
     
  • GBP/EUR

    1.1854
    +0.0034 (+0.29%)
     
  • GBP/USD

    1.2085
    -0.0054 (-0.45%)
     
  • BTC-GBP

    19,981.40
    -406.35 (-1.99%)
     
  • CMC Crypto 200

    573.62
    -17.14 (-2.90%)
     
  • S&P 500

    4,271.19
    -8.96 (-0.21%)
     
  • DOW

    33,739.59
    -21.46 (-0.06%)
     
  • CRUDE OIL

    88.38
    -3.71 (-4.03%)
     
  • GOLD FUTURES

    1,791.90
    -23.60 (-1.30%)
     
  • NIKKEI 225

    28,871.78
    +324.80 (+1.14%)
     
  • HANG SENG

    20,040.86
    -134.76 (-0.67%)
     
  • DAX

    13,792.45
    -3.40 (-0.02%)
     
  • CAC 40

    6,554.43
    +0.57 (+0.01%)
     

Global Checkpoint Inhibitors Markets, Analysis & Forecasts, 2016-2021, 2021-2026F, 2031F Featuring AstraZeneca, Bristol-Myers Squibb, Merck & Co, Roche, Pfizer, Incyte, Novartis, and NewLink Genetics

·7-min read
Company Logo
Company Logo

Global Checkpoint Inhibitors Market

Global Checkpoint Inhibitors Market
Global Checkpoint Inhibitors Market

Dublin, July 29, 2022 (GLOBE NEWSWIRE) -- The "Checkpoint Inhibitors Global Market Report 2022: By Drug, By Application, By End-Users" report has been added to ResearchAndMarkets.com's offering.

Major players in the checkpoint inhibitors market are AstraZeneca PLC, Bristol-Myers Squibb Company, Merck & Co., Inc., Roche Holding AG, Pfizer, Incyte Corporation, Novartis AG, and NewLink Genetics Corporation.

The global checkpoint inhibitors market is expected to grow from $19.86 billion in 2021 to $23.93 billion in 2022 at a compound annual growth rate (CAGR) of 20.5%. The market is expected to reach $46.27 billion in 2026 at a CAGR of 17.9%.

The checkpoint inhibitors market consists of sales of the immune checkpoint inhibitor drugs and related services by entities (organizations, sole traders and partnerships) that produce checkpoint inhibitors for treating cancer. A checkpoint inhibitor is a drug that blocks proteins that stop the body's immune system from killing the cancer cells. One type of cell in the immune system that fights the cancer cells are T-cells. T cells have proteins on them that turn on immune response and other proteins that turn it off.

These are called checkpoints. Some checkpoints help T-cells to become active while others help T-cells to switch off. When cancer cells produce high levels of proteins, the switch off checkpoints restrict the immune responses from being strong and sometimes even stops the T-cells from killing the cancer cells. When the checkpoints are blocked by the checkpoint inhibitor from binding with its partner proteins, this allows the T-cells to kill the cancer cells.

The main types of drugs in checkpoint inhibitors are PD-1 inhibitors, PD-L1 inhibitors, CTLA-4, chimeric antigen receptor T-cell and others. PD-1 inhibitors and PD-L1 inhibitors are anticancer checkpoint inhibitors which impede the action of the immune checkpoint proteins PD-1 and PDL1 on the cell surface. It is used in lung cancer, renal cancer, blood cancer, bladder cancer, melanoma, others and implemented in various sectors such as hospitals pharmacies, retail pharmacies, online pharmacies.

North America is the largest region in the checkpoint inhibitors market in 2021. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the checkpoint inhibitors market during the forecast period. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. The four most common types of cancers worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Checkpoint inhibitors targeting the checkpoints are very helpful as cancer therapies. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the checkpoint inhibitors market.

The high cost of checkpoint inhibitor cancer treatment is expected to limit the checkpoint inhibitor market. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, the lack of cost-effective therapies for cancer has influenced the health conditions of the population and has led to a low-average life expectancy.

For instance, the cost for a course of intravenous checkpoint inhibitor therapy is around $150,000 to $250,000, which is very expensive, especially for countries without public insurance. Therefore, the high cost of checkpoint inhibitor cancer treatment is expected to limit the checkpoint inhibitor market.

Major companies in the checkpoint inhibitor market are forming partnerships or collaborations for the development of advanced technologies such as bifunctional fusion protein or Y-trap. Most of the patients with cancer do not respond to immune checkpoint inhibitors.

To make immunotherapies more effective, a group of researchers has developed the bifunctional fusion protein or Y-trap. This drug is created by fusing a receptor for a protein called TGF-beta that targets checkpoint protein such as PD-L1 or CTLA-4. Y- Trap targets both a checkpoint inhibitor and TGF-beta and gives a more effective way to block the immune suppression and destroys the cancer cells.

Merck, a prominent science and technology group, and GSK, a research-based global healthcare company, have announced that they have entered into a global strategic partnership to jointly create and market M7824 (bintrafusp alfa). M7824 is an investigational bi-functional fusion protein immunotherapy that is currently in clinical research, including possible registration trials, for various difficult-to-treat cancers.

This includes a Phase II study to investigate M7824 compared to pembrolizumab as a first-line treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC). In another instance, in June 2020, Targovax, a Norway-based biotechnology company that develops immune activators for targeting solid tumors, entered into a collaboration with Leidos' Explorations in Global Health (ExGloH) division for evaluating the potential of using ONCOS, a Targovax's clinical program of oncolytic adenoviruses, as a vector to encode MicrotideT checkpoint inhibitor peptides.

In June 2020, Targovax, a Norway-based biotechnology company, entered into a collaboration with the Explorations in Global Health (ExGloH) division of Leidos for evaluating the potential of using ONCOS, a Targovax's clinical program of oncolytic adenoviruses, as a vector to encode Microtide checkpoint inhibitor peptides.

Explorations in Global Health (ExGloH) division of Leidos has created a specific, proprietary portfolio of microbially-derived peptides called MicrotideTM that act as immune checkpoint inhibitors. Leidos is a US-based company that deals with defense, aviation, information technology, and biomedical research.

Key Topics Covered:

1. Executive Summary

2. Checkpoint Inhibitors Market Characteristics

3. Checkpoint Inhibitors Market Trends And Strategies

4. Impact Of COVID-19 On Checkpoint Inhibitors

5. Checkpoint Inhibitors Market Size And Growth
5.1. Global Checkpoint Inhibitors Historic Market, 2016-2021, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Checkpoint Inhibitors Forecast Market, 2021-2026F, 2031F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. Checkpoint Inhibitors Market Segmentation
6.1. Global Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

  • PD-1 Inhibitors

  • PD-L1 Inhibitors

  • CTLA-4

  • Chimeric Antigen Receptor T-cell

  • Others

6.2. Global Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

  • Lung Cancer

  • Renal Cancer

  • Blood Cancer

  • Bladder Cancer

  • Melanoma

  • Others

6.3. Global Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

  • Hospitals Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

7. Checkpoint Inhibitors Market Regional And Country Analysis
7.1. Global Checkpoint Inhibitors Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7.2. Global Checkpoint Inhibitors Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

Companies Mentioned

  • AstraZeneca plc.

  • Bristol-Myers Squibb Company

  • Merck & Co. inc.

  • Roche Holding AG

  • Pfizer inc.

  • yte Corporation

  • Novartis AG

  • NewLink Genetics Corporation

  • Seattle Genetics

  • Celldex Therapeutics

  • GlaxoSmithKline plc.

  • Innate Pharma S.A.

  • Ono Pharmaceutical Co. Ltd.

  • Juno Therapeutics

  • Kite Pharma

  • Eli Lilly and Company (ARMO Biosciences)

  • Fortress Biotech

  • ArGEN-X

  • MacroGenics

  • CureTech

  • Sorrento Therapeutics

  • Sanofi

For more information about this report visit https://www.researchandmarkets.com/r/86jpt8

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting